43.92

2.86% 1.22

Exelixis Inc (EXEL)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché EXEL Giù? Forum Previsione

Precedente Chiudi:

$42.70

Aprire:

$42.89

Volume 24 ore:

2.05M

Relative Volume:

0.80

Capitalizzazione di mercato:

$11.41B

Reddito:

$2.29B

Utile/perdita netta:

$677.90M

Rapporto P/E:

18.49

EPS:

2.3753

Flusso di cassa netto:

$779.77M

1 W Prestazione:

+0.05%

1M Prestazione:

-0.36%

6M Prestazione:

+14.11%

1 anno Prestazione:

+27.34%

Intervallo 1D:

$42.73

$44.05

Intervallo di 1 settimana:

$40.92

$44.28

Portata 52W:

$32.38

$49.62

Exelixis Inc Stock (EXEL) Company Profile

Nome

Exelixis Inc

Settore

Healthcare (1111)

Industria

Biotechnology (622)

Telefono

(650) 837-7000

Indirizzo

1851 HARBOR BAY PARKWAY, ALAMEDA, CA

Dipendente

1,077

Cinguettio

@exelixisinc

Prossima data di guadagno

2025-07-28

Ultimi documenti SEC

EXEL's Discussions on Twitter

Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
EXEL Exelixis Inc	43.92	11.09B	2.29B	677.90M	779.77M	2.3753
VRTX Vertex Pharmaceuticals Inc	491.47	117.98B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	803.17	82.85B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	821.96	51.58B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	314.40	40.75B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.07	38.33B	4.98B	69.60M	525.67M	0.5198

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2026-01-05	Downgrade	BofA Securities	Neutral → Underperform
2025-11-18	Iniziato	Wolfe Research	Peer Perform
2025-11-03	Downgrade	Guggenheim	Buy → Neutral
2025-10-21	Aggiornamento	Leerink Partners	Market Perform → Outperform
2025-09-19	Ripresa	Barclays	Equal Weight
2025-09-17	Ripresa	Barclays	Equal Weight
2025-09-17	Iniziato	Goldman	Buy
2025-07-08	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-06-24	Aggiornamento	Stephens	Equal-Weight → Overweight
2025-02-24	Downgrade	Wells Fargo	Overweight → Equal Weight
2025-01-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2025-01-24	Downgrade	Oppenheimer	Outperform → Perform
2024-12-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
2024-12-17	Downgrade	BofA Securities	Buy → Neutral
2024-10-16	Reiterato	RBC Capital Mkts	Outperform
2024-09-19	Iniziato	UBS	Neutral
2024-04-11	Downgrade	Barclays	Overweight → Equal Weight
2023-12-19	Iniziato	BTIG Research	Buy
2023-12-15	Iniziato	Citigroup	Buy
2023-09-26	Iniziato	H.C. Wainwright	Buy
2023-08-22	Reiterato	Oppenheimer	Outperform
2023-08-08	Iniziato	SVB Securities	Market Perform
2023-07-11	Ripresa	Morgan Stanley	Equal-Weight
2023-05-10	Ripresa	Piper Sandler	Overweight
2023-03-09	Iniziato	Wells Fargo	Overweight
2023-01-26	Iniziato	Credit Suisse	Outperform
2022-10-18	Iniziato	JMP Securities	Mkt Outperform
2022-06-24	Iniziato	BMO Capital Markets	Outperform
2021-11-19	Iniziato	Piper Sandler	Overweight
2021-11-03	Ripresa	Jefferies	Buy
2021-10-07	Iniziato	Jefferies	Buy
2021-08-06	Reiterato	H.C. Wainwright	Buy
2021-06-15	Iniziato	H.C. Wainwright	Buy
2021-05-18	Ripresa	Goldman	Sell
2021-03-31	Iniziato	Credit Suisse	Outperform
2021-03-12	Iniziato	Wolfe Research	Outperform
2020-03-04	Iniziato	Barclays	Overweight
2020-01-13	Iniziato	SunTrust	Buy
2019-11-13	Iniziato	BofA/Merrill	Buy
2019-03-18	Aggiornamento	Morgan Stanley	Underweight → Equal-Weight
2018-09-17	Iniziato	Goldman	Neutral
2018-09-10	Iniziato	Morgan Stanley	Underweight
2018-05-11	Reiterato	Needham	Buy
2017-10-17	Reiterato	Needham	Buy
2017-10-17	Reiterato	RBC Capital Mkts	Outperform
2017-10-16	Reiterato	SunTrust	Buy
2017-09-22	Downgrade	Leerink Partners	Outperform → Mkt Perform
2017-09-15	Iniziato	RBC Capital Mkts	Outperform
2017-09-12	Reiterato	Needham	Buy
2017-07-14	Iniziato	SunTrust	Buy
2017-03-31	Iniziato	Needham	Buy
2017-03-16	Iniziato	Oppenheimer	Perform
2017-02-28	Downgrade	Stifel	Buy → Hold
2016-11-03	Iniziato	Deutsche Bank	Buy
2016-10-10	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-09-15	Reiterato	Stifel	Buy

Mostra tutto

Exelixis Inc Borsa (EXEL) Ultime notizie

04:06 AM

Illinois Municipal Retirement Fund Boosts Position in Exelixis, Inc. $EXEL - MarketBeat

04:06 AM

01:59 AM

Exelixis (NASDAQ:EXEL) Downgraded by Wall Street Zen to "Buy" - MarketBeat

01:59 AM

Feb 13, 2026

Aug Wrap: What is the earnings history of Exelixis IncWeekly Earnings Recap & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Feb 13, 2026

Assetmark Inc. Has $131.99 Million Stock Position in Exelixis, Inc. $EXEL - MarketBeat

Feb 13, 2026

Exelixis (EXEL) Q4 2025 Earnings Call Transcript - AOL.com

Feb 13, 2026

Feb 12, 2026

Exelixis stock price target raised to $54 from $52 at H.C. Wainwright - Investing.com Nigeria

Feb 12, 2026

Exelixis (EXEL) Receives a Buy from Stephens - The Globe and Mail

Feb 12, 2026

RBC Capital Sticks to Its Hold Rating for Exelixis (EXEL) - The Globe and Mail

Feb 12, 2026

Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and OrganiGram Holdings (OGI) - The Globe and Mail

Feb 12, 2026

Exelixis Reports Solid Earnings-Are New Highs Back on the Table? - Finviz

Feb 12, 2026

Exelixis Reports Solid Earnings—Are New Highs Back on the Table? - MarketBeat

Feb 12, 2026

Exelixis stock price target raised to $54 from $52 at H.C. Wainwright By Investing.com - Investing.com South Africa

Feb 12, 2026

Westover Capital Advisors LLC Grows Stake in Exelixis, Inc. $EXEL - MarketBeat

Feb 12, 2026